Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials

Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials

Afatinib is an effective therapy for metastatic non-small cell lung cancer (NSCLC) but it is associated with a relatively high incidence of severe diarrhea. The association between pre-treatment candidate predictors (age, sex, race, performance status, renal function, hemoglobin, and measures of bod...

Full description

Bibliographic Details
Main Authors: Ashley M. Hopkins, Anh-Minh Nguyen, Christos S. Karapetis, Andrew Rowland, Michael J. Sorich
Format: Article
Language:English
Published: MDPI AG 2018-10-01
Series:Cancers
Subjects:
EGFR inhibitor
diarrhea
toxicity
prediction model
adverse event
Online Access:http://www.mdpi.com/2072-6694/10/10/384

Internet

http://www.mdpi.com/2072-6694/10/10/384

Similar Items